appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, *e.g.*, permitting electronic submission of responses.

Overview of This Information Collection

(1) Type of Information Collection: Proposed collection; comments requested.

(2) *Title of the Form/Collection:* Community Policing Self-Assessment (CP–SAT).

(3) Agency form number, if any, and the applicable component of the Department sponsoring the collection: None. U.S. Department of Justice Office of Community Oriented Policing Services.

(4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Law Enforcement Agencies and community partners. The purpose of this project is to improve the practice of community policing throughout the United States by supporting the development of a series of tools that will allow law enforcement agencies to gain better insight into the depth and breadth of their community policing activities.

(5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond/reply: It is estimated that approximately 800 respondents will respond with an average of 1 hour per response.

(6) An estimate of the total public burden (in hours) associated with the collection: The total estimated burden is 800 hours across 103 agencies.

If additional information is required contact: Lynn Bryant, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Patrick Henry Building, Suite 1600, 601 D Street, NW., Washington, DC 20530.

Dated: February 3, 2009.

Lynn Bryant,

Department Clearance Officer, PRA, United States Department of Justice.

[FR Doc. E9–2585 Filed 2–5–09; 8:45 am]

BILLING CODE 4410-AT-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Application

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on December 19, 2008, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II:

Phenylacetone (8501) II	Drug	Schedule
Coca Leaves (9040) II Opium, raw (9600) II Poppy Straw (9650) II Poppy Straw Concentrate (9670) II	Coca Leaves (9040)	

The company plans to import the listed controlled substances for the manufacture of controlled substances in bulk for distribution to its customers.

No comments, objections, or requests for any hearings will be accepted on any application for registration or reregistration to import crude opium, poppy straw, concentrate of poppy straw or coca leaves. As explained in the Correction to Notice of Application pertaining to Rhodes Technologies, 72 FR 3417 (2007), comments and requests for hearings on applications to import narcotic raw material are not appropriate.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate,

to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA 22152; and must be filed no later than March 9, 2009.

This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: January 30, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–2543 Filed 2–5–09; 8:45 am] **BILLING CODE 4410–09–P**

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 9, 2008 and published in the **Federal Register** on October 17, 2008 (73 FR 61909), Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Cathinone (1235)	1
Methcathinone (1237)	1
N-Ethylamphetamine (1475)	1
N,N-Dimethylamphetamine (1480)	1
Aminorex (1585)	1
4-Methylaminorex (cis isomer) (1590)	1
Gammá-Hydroxybutyric acid (2010)	1
Methaqualone (2565)	1
Alpha-ethyltryptamine (7249)	1

Drug	Schedule
	Concadio
Lysergic acid diethylamide (7315)	1
Tetrahydrocannabinols (7370)	i
Mescaline (7381)	1
3,4,5-Trimethoxyamphetamine (7390)	!
4-Bromo-2,5-dimethoxyamphetamine (7391)	1
4-Methyl-2,5-dimethoxyamphetamine (7395)	i
2,5-Dimethoxyamphetamine (7396)	İ
2,5-Dimethoxy-4-ethylamphetamine (7399)	1
3,4-Methylenedioxyamphetamine (7400)	1
N-Hydroxy-3,4-methylendioxyamphetamine (7402)	i
3,4-Methylendioxy-N-ethylamphetamine (7404)	İ
3,4-Methylenedioxymethamphetamine (7405)	!
4-Methoxyamphetamine (7411)	1
Bufotenine (7433)	i
Diethyltryptamine (7434)	İ
Dimethyltryptamine (7435)	!
Psilocypin (7437)	1
Psilocyn (7438)	Í
Acetyldihydrocodeine (9051)	İ
Benzylmorphine (9052)	1
Codeine-N-oxide (9053)	1
Dihydromorphine (9145)	1
Hydromorphinol (9301)	i
Methyldihydromorphine (9304)	1
Morphine-N-oxide (9307)	!
Normorphine (9313)	1
Acetylmethadol (9601)	i
Allylprodine (9602)	1
Alphacetylmethadol except levo-alphacetylmethadol (9603)	ļ
Alphameprodine (9604)	1
Betacetylmethadol (9607)	i
Betameprodine (9608)	1
Betamethadol (9609)	!
Betaprodine (9611)	1
Noracymethadol (9633)	i
Norlevorphanol (9634)	
Normethadone (9635)	1
Trimeperidine (9646)	1
Para-Fluorofentanyl (9812)	i
3-Methylfentanyl (9813)	İ
Alpha-Methylfentanyl (9814)	!
Acetyl-alpha-methylfentanyl (9815)	1
Beta-hydroxyrentariyr (9830) Beta-hydroxy-3-methylfentanyl (9831)	İ
Alpha-Methylthiofentanyl (9832)	1
3-Methylthiofentanyl (9833)	!
Thiofentanyl (9835)	I II
Amphetamine (1100)	II II
Phenmetrazine (1631)	ii
Methylphenidate (1724)	II
Amobarbital (2125)	II II
Pentobarbital (2270)	II II
Glutethimide (2550)	ii
Nabilone (7379)	ii
1-Phenylcyclohexylamine (7460)	II.
Phencyclidine (7471)	11
1-Piperidinocyclohexanecarbonitrile (8603) Alphaprodine (9010)	II II
Cocaine (9041)	ii
Codeine (9050)	II
Dihydrocodeine (9120)	II II
Oxycodone (9143)	II

Drug	Schedule
Hydromorphone (9150)	П
Hydromorphone (9150) Diphenoxylate (9170)	II
Benzoylecgonine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Isomethadone (9226)	II
Meperidine (9230)	II
Meperidine intermediate-A (9232)	II
Meperidine intermediate-B (9233)	II
Meperidine intermediate-C (9234)	II
Methadone (9250)	II
Methadone intermediate (9254)	II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	II
Thebaine (9333)	II
Levo-alphacetylmethadol (9648)	II
Oxymorphone (9652)	II
Noroxymorphone (9668)	III
Racemethorper	II
Alfentanii (9737)	II
Sufentanil (9740)	III
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cerilliant Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cerilliant Corporation to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: January 30, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9-2541 Filed 2-5-09; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated October 7, 2008 and published in the **Federal Register** on October 14, 2008, (73 FR 60719), Halo Pharmaceutical Inc., 30 North Jefferson Road, Whippany, New Jersey 07981, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II:

Drug	Schedule
Dihydromorphine (9145)	I
Hydromorphone (9150)	II

Dihydromorphine is an intermediate in the manufacture of Hydromorphone and is not for commercial distribution. The company plans to manufacture Hydromorphone HCL for sale to other manufacturers and for the manufacture of other controlled substance dosage units for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Halo Pharmaceutical Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Halo Pharmaceutical Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical

security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: January 30, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E9–2538 Filed 2–5–09; 8:45 am] **BILLING CODE 4410–09–P**

DEPARTMENT OF LABOR

Employment and Training Administration

Employment and Training
Administration Notice of
Implementation of Supplemental
Appropriations Act, 2008, Title IV—
Emergency Unemployment
Compensation, and the Unemployment
Compensation Extension Act

AGENCY: Employment and Training Administration, Labor.

ACTION: Notice.

SUMMARY: The Employment and Training Administration (ETA) of the United States Department of Labor (the Department) is publishing, for public information, notice of the issuance and availability of the Unemployment Insurance Program Letters (UIPL) that